RxDoctor Payments Data

Mandy Ramani, MD

Dermatopathology · la Canada, CANPI 1497750640

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Sanofi at 27.7% of the total. Among dermatopathology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,074in general payments, 2019–2025

Across 323 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Sun Pharmaceutical Industries Inc.$922
  • Regeneron Healthcare Solutions, Inc.$874
  • AbbVie$692
  • Lilly USA, LLC$384
  • Galderma Laboratories, L.p.$297
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$7,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,074 in reported general payments places this provider in the 90th percentile of 76 dermatopathology providers in California.

See all dermatopathology providers in California

Medicare billing

Part B allowed, 2024
$191,999
Medicare patients
564
Services billed
2,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab14$102,350
Dupixent SyringeDupilumab14$53,639
Clobetasol Propionate41$1,877
Fluocinonide43$1,441
Metronidazole16$1,082
Tretinoin17$1,023
Spironolactone34$651
Betamethasone Dipropionate17$582
Ketoconazole46$544
Minoxidil60$449
Triamcinolone Acetonide64$395
Minocycline Hcl14$381
Fluconazole14$321
Hydrocortisone24$105

Paid to pharmacies, not to this prescriber.

Other dermatopathology in la Canada

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →